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Abstract: INTRODUCTION: Congenital myasthenic syndromes are rare. Mutations in MUSK were first
described in 2004. Thirteen patients have been reported to date, mostly with a relatively mild course.
The molecular diagnosis has implications for choice of treatment and genetic counseling. METHODS:
Clinical course and electrophysiological, pathological, and genetic findings were assessed. RESULTS: We
describe the case of a boy with prenatal onset and severe respiratory symptoms with a persisting need
for ventilation. The patient had severe bulbar symptoms, marked axial weakness causing a ”dropped
head,” and some facial and proximal weakness. Ophthalmoparesis developed during the first year of life.
Salbutamol led to improvement, 3,4-diaminopyridine had a modest effect, but pyridostigmine produced
deterioration. Two novel mutations in MUSK were found by whole exome sequencing. CONCLUSIONS:
We expand the phenotype of congenital myasthenic syndromes with MUSK mutations, describing a more
severe clinical course with prenatal onset. Predominant bulbar and respiratory weakness with facial and
axial weakness and ophthalmoparesis are diagnostic clues.
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ABSTRACT: Introduction: Congenital myasthenic syndromes
are rare. Mutations in MUSK were first described in 2004. Thir-
teen patients have been reported to date, mostly with a rela-
tively mild course. The molecular diagnosis has implications for
choice of treatment and genetic counseling. Methods: Clinical
course and electrophysiological, pathological, and genetic find-
ings were assessed. Results: We describe the case of a boy
with prenatal onset and severe respiratory symptoms with a
persisting need for ventilation. The patient had severe bulbar
symptoms, marked axial weakness causing a “dropped head,”
and some facial and proximal weakness. Ophthalmoparesis
developed during the first year of life. Salbutamol led to
improvement, 3,4-diaminopyridine had a modest effect, but pyri-
dostigmine produced deterioration. Two novel mutations in
MUSK were found by whole exome sequencing. Conclusions:
We expand the phenotype of congenital myasthenic syndromes
with MUSK mutations, describing a more severe clinical course
with prenatal onset. Predominant bulbar and respiratory weak-
ness with facial and axial weakness and ophthalmoparesis are
diagnostic clues.
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Congenital myasthenic syndromes (CMS) are rare
genetic conditions affecting genes that code for
proteins involved in neuromuscular transmission.
So far, 20 causative genes have been identified,1–4
including genes that code for the acetylcholine
receptor subunits CHRNE, CHRNA1, CHRNB1,
CHRND, and CHRNG, and the intracellular pro-
teins RAPSYN and DOK7. Mutations in MUSK [the
gene that codes for muscle-specific tyrosine kinase
(MuSK)] are very rare. The first description was
published 2004 by Chevessier et al.,5 and since
then only 10 different MUSK mutations in a total
of 13 patients have been described (7 missense
mutations, 7 small single-basepair indels, and a 2-
exon deletion).5–10 The main clinical features
described were facial and bulbar weakness, ptosis,
and external ophthalmoplegia in most cases; respi-
ratory problems, such as respiratory failure at birth
or with respiratory infections, or neonatal stridor;
and proximal and axial weakness with fatigability
on walking. The further clinical course was gener-
ally described as mild, except for 1 patient who
had a severe course with neonatal onset, respira-
tory failure, vocal cord paralysis, and need for tra-
cheostomy. He died at 1.5 years of age.5 All other
patients were able to walk. Respiratory problems
were reported mostly in infancy, except for 1
patient who still needed nocturnal ventilation at
age 19 years.8 Patients were reported to respond to
salbutamol6,8 or 3,4-diaminopyridine,5,7 but there
was no or only a temporary response to pyridostig-
mine or ephedrine.
We describe the case of a boy with prenatal
onset and a severe clinical course, which expands
the previously described phenotype. Using whole
exome sequencing, 2 novel deleterious compound
heterozygous mutations in MUSK were detected.
CASE REPORT
At his last visit the patient was a 4-year-old boy
who was born at term to a non-consanguineous
German couple. During pregnancy, polyhydram-
nios and bilateral club feet were noted at 23 weeks
gestation without evidence of maternal diabetes.
At birth he presented with respiratory failure
and was intubated. He had pes equinovarus on the
left, a flat foot on the right, and bilateral hip dys-
plasia. He subsequently needed tracheostomy, as
bilateral vocal cord palsy was also diagnosed. Wean-
ing from mechanical ventilation was not possible
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due to repeated respiratory crises. In addition to
the prominent respiratory problems there was axial
muscle hypotonia, but he retained good antigravity
movements of the legs more than the arms. Muscle
biopsy showed variability of fiber size and type 2
fiber predominance. Because of the bilateral vocal
cord palsy, a CMS was considered. At age 3
months, a test dose of pyridostigmine was given,
which led to bradycardia and respiratory crisis and
was therefore stopped. At 9 months, bilateral pto-
sis, external ophthalmoplegia, and some facial
weakness were first noted. He had minor facial dys-
morphism with uplifted ear lobes, hypoplasia of
the supraorbital ridges, deep-set eyes, infraorbital
creases, and bilateral single palmar creases with
increased white lines (Fig. 1). A possible myas-
thenic syndrome was re-evaluated, and treatment
with salbutamol liquid 3 3 0.15 mg/kg was started.
This led to marked improvement in respiration,
and weaning to a home ventilator was possible.
Stimulated single-fiber electromyography11,12 at
13 months showed increased jitter [average mean
consecutive difference (MCD) was 69 ls (normal
26), no blocking].
This also indicated a disorder of neuromuscu-
lar transmission, although 3-HZ repetitive stimula-
tion of the facial nerve did not show decrement.
Motor development was delayed, but steadily
improved. At age 2.5 years, he was able to stand up
without help and started walking. At 4 years he
could climb stairs. He had marked facial and axial
weakness leading to a “dropped head” and had
moderate, predominantly proximal, muscle weak-
ness affecting arms more than legs (Fig. 2). Clear
fatigability was only noted after age 3. Marked swal-
lowing problems have persisted from birth. Despite
treatment, only small amounts of oral feeding are
currently possible, and he is fed via gastrostomy.
Mechanical ventilation is still necessary, although
mainly during sleep at night and continuously dur-
ing infections. The vocal cord palsy persists. Pes
equinovarus resolved with physiotherapy. At 4 years
he had a rigid spine but no scoliosis. Speech and
cognitive development were normal.
In addition to the neuromuscular problem,
brain MRI demonstrated a lesion in the left middle
cerebral artery territory, which was attributed to
perinatal hypoxic/ischemic injury leading to mini-
mally increased muscle tone in the right leg.
Sanger sequencing of DOK7, investigated
because of the response to treatment and stridor,
COLQ because of the response to treatment and
respiratory difficulties, and CHRNE, investigated
because of the striking ophthalmoplegia, did not
show pathogenic variants. Whole exome sequenc-
ing revealed compound heterozygous mutations in
the MUSK gene [c.308A>G/5 (p.Asn103Ser/5),
exon 3; c.496C>T/5 (p.Arg166*/5), exon 5,
FIGURE 1. Clinical pictures of the patient at age 9 months (A, B) and at 3 years (C–E). Note the changing facial phenotype with nor-
malizing ear lobe position but persistent poor head control.
MUSK Case Report MUSCLE & NERVE October 2015 669
both novel and each inherited in trans from each
parent], establishing the final diagnosis.
After receiving the genetic diagnosis 3,4-diami-
nopyridine was added, and mild further improve-
ment with increased stamina at a dose of 0.9 mg/
kg/day was noted.
METHODS
Whole exome sequencing (WES) on genomic
DNA extracted from peripheral blood lymphocytes
of the patient was performed using a 70-Mbase
genome-sequencing kit (SureSelectXT HumanAl-
lExon V41UTRs kit; Agilent Technologies) and
with 65-bp forward and 30 reverse reads on
another sequencing system (SOLiD 5500xl; ABI/
Life Technologies). The average depth of coverage
was 923, and about 88% of the targeted bases
were assessed by 6 independent sequence reads.
The candidate MUSK variants from WES were
confirmed after polymerase chain reaction (PCR)
amplification by Sanger sequencing using a genetic
analyzer (ABI 3730; Applied Biosystems, Foster
City, California).
The structural role of Asn103 was assessed
based on the MuSK crystal structure (PDB code
2IEP).13 The Asn103Ser mutation was generated
with Swiss-PDB Viewer,14 and RasMol15 was used
for structural analysis and visualization.
Results of Mutational Analysis. WES in the patient
revealed 2 heterozygous mutations within the cod-
ing region of the MUSK gene. One mutation
located in exon 3 was a missense mutation affect-
ing an evolutionarily highly conserved amino acid
[c.308A>G/5 (p.Asn103Ser/5] and was predicted
to be deleterious by 4 of 6 prediction tools applied
(deleterious according to SIFT, PolyPhen, LRT,
and Mutation Taster, tolerated according to Muta-
tion assessor and FATHMM). The second mutation
located in exon 5 was a stop mutation leading to
premature truncation of the protein [c.496C>T/5
(p.Arg166*/5)]. Both mutations were confirmed
by Sanger sequencing and were shown to be com-
pound heterozygous, as both parents, in addition
to the wild-type, carried only 1 mutation each (Fig.
3). To further evaluate the functional effects, com-
putational modeling of the mutant alleles on the
protein structure was performed.
MuSK is a transmembrane protein containing a
total of 5 domains. The extracellular N-terminus
comprises 3 Ig-fold domains (residues 28–119,
121–208, 212–301) and 1 cysteine-rich domain
(residues 317–448). The intracellular C-terminal
part harbors the kinase domain (residues 575–
856).
An Arg166* stop mutation thus lacks most of
the extracellular domains as well as the kinase
domain and is therefore expected to be catalyti-
cally inactive.
FIGURE 2. Clinical pictures of the patient at 4 years of age. Note the “dropped head” posture.
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The Asn103Ser mutation is located in the first
Ig-fold domain (Ig1), for which the crystal struc-
ture is known.13 Based on the predicted effect of
the Asn103Ser mutation on Ig1 stability and the
functional importance of this domain as an agrin
binding site, it is expected that an Asn103Ser
mutation would lead to severe functional impair-
ment of MuSK (Fig. 4). In the wild type, the side
chain of Asn103 forms a hydrogen bond to the
backbone carboxyl group of Lys26, which is
located at the very N-terminus of the Ig1 domain
(Fig. 4A and B). Due to the shorter side chain of
the serine, the respective hydrogen bond cannot
be formed in the Asn103Ser mutant (Fig. 4C and
D), which is expected to lead to significant destabi-
lization of the N-terminus of the domain and may
even cause unfolding of the entire domain. Previ-
ous experimental studies have demonstrated that
the Ig1 is very sensitive to removal of stabilizing
interactions. For example, the mutation of a non-
canonical disulfide bridge in Ig1 results in
improper folding and processing of MuSK.13
DISCUSSION
CMS with MUSK mutations are very rare. Until
now, only 13 patients from 6 families have been
reported. The reported phenotype in these
patients comprises a lack of response to pyridostig-
mine, stridor/vocal cord palsy, and the need for
ventilatory support, especially during the neonatal
period and during infections. Furthermore, facial
weakness, ptosis, and ophthalmoplegia are
described commonly (10 of 13 patients). Six of the
13 patients had bulbar symptoms. The distribution
of limb girdle weakness was reported as mostly
proximal and axial. Onset in all patients was
before age 3 years, with neonatal onset in 6
patients, where reported.5–10
We expand this phenotypic spectrum with a
more severe and earlier prenatal onset; this
includes polyhydramnios, contractures at birth,
and severe respiratory and swallowing problems
from birth, persisting at age 4 years. The distribu-
tion of weakness is similar to the reported cases
with predominant axial and facial weakness, ptosis,
and ophthalmoplegia, but with the weakness being
more severe, leading to a “dropped head,” only
partially ameliorated by treatment. As reported in
other patients, he responded well to salbutamol
and showed some further improvement with 3,4-
diaminopyridine, but a pyridostigmine trial in
infancy led to dramatic worsening.
We suggest that MUSK mutations be considered
in patients with clinical suspicion of CMS with
marked bulbar, respiratory, and axial weakness.
Severe congenital respiratory weakness, stridor
due to bilateral vocal cord palsy, and bulbar weak-
ness in the absence of marked weakness have also
been described in patients with DOK7 CMS.16
Other forms of CMS (RAPSN, CHAT, and fast-
channel CMS) are also associated with early respi-
ratory crises and bulbar weakness, but often weak-
ness in these patients is more pronounced. Of
note is that the development of external ophthal-
moplegia and ptosis, which helps to distinguish
from the phenotype described in DOK7 patients,
was delayed in the patient we have described.
The “dropped head,” as a sign of severe axial
weakness, was a prominent feature in this patient.
However, it is not specific for MUSK, having been
described in other CMS and in congenital muscu-
lar dystrophies.17,18
FIGURE 3. Partial electropherograms of the MUSK gene mutations in the patient and parents. This confirms compound heterozygosity
for the mutations c.308A>G/5 (p.Asn103Ser/5), in exon 3, and c.496C>T/5 (p.Arg166*/5), in exon 5.
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Orthopedic problems are seen quite often in the
clinical course of COLQ patients, especially scolio-
sis.19 Scoliosis often develops in patients with DOK7
mutations, but in the 13 patients with MUSK muta-
tions from the literature, it was reported in only 1
patient.8 Our patient had pes equinovarus at birth, but
it resolved with physiotherapy. He developed a rigid
spine without scoliosis by age 4 years.
Repetitive nerve stimulation may fail to show
decrement in CMS,20 but stimulated single-fiber
electromyography shows11,12 increased jitter. Elec-
trophysiological investigations may be helpful for
differentiation of CMS caused by mutations in
COLQ, as in some patients with these mutations
double compound muscle action potentials can be
found after a single stimulus.19 CMS caused by
mutations in RAPSN or CHAT and fast-channel syn-
dromes can also present with respiratory problems,
but would be expected to show more generalized
weakness and would respond well to pyridostig-
mine. It should be noted that testing for a
response to pyridostigmine can be dangerous, as
in some CMS it can lead to worsening or even
acute life-threatening events, as seen in the patient
described in this report.
Interestingly, patients with MuSK antibody-
positive myasthenia also have more bulbar, respira-
tory, and axial muscle weakness than patients with
antibodies against the acetylcholine receptor.21
In conclusion, CMS with MUSK mutations is
very rare. Most patients reported to date have a rel-
atively mild phenotype, but as shown here a more
severe phenotype with prenatal onset is possible.
Predominant bulbar and respiratory weakness with
FIGURE 4. Effect of the Asn103Ser mutation on MuSK structure. (A) In wild-type MuSK, the side chain of Asn103 forms a hydrogen
bond (bold arrow) to the backbone carboxyl group of Lys26. (B) Enlargement shows the interacting groups. The distance of 2.1 A˚ indi-
cates the presence of a stable hydrogen bond. (C) Location of Ser103 in the Asn103Ser mutant. (D) Enlargement showing the relative
orientation of Lys26 and Ser103. The distance of 4.9 A˚ between both residues (black dotted line) is too large for the formation of a
hydrogen bond.
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later development of facial and axial weakness, a
“dropped head,” and ophthalmoparesis may point
to the diagnosis.
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ABSTRACT: Introduction: X-linked myopathy with excessive
autophagy (XMEA) is an X-linked recessive myopathy due to
recently reported mutations in the VMA21 gene. Methods: Four
men from 2 separate families were studied. The clinical presen-
tation, genetic data, muscle biopsy, and muscle MRI were ana-
lyzed. Results: A known VMA21 mutation, c.16314A>G, and a
new mutation, c.16313A>G, respectively, were found in the 2
families. The clinical course was characterized by onset in child-
hood and progressive muscle weakness with a limb-girdle pattern.
Muscle biopsy revealed a mild myopathy with an increased num-
ber of giant autophagic vacuoles. Whole-body muscle MRI
showed that pelvic girdle and proximal thighs were the most and
earliest affected territories, with sparing of rectus femoris muscles.
Muscle changes essentially consisted of degenerative fatty
replacement. Conclusions: This study highlights a distinctive MRI
pattern of muscle involvement, which can be helpful for diagnosis
of XMEA, even before muscle biopsy or genetic analysis.
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X-linked myopathy with excessive autophagy
(XMEA) is a rare childhood-onset disease charac-
terized by progressive vacuolation and atrophy of
Abbreviations: AM, adductus magnus; BF, biceps femoris; CK, creatine
kinase; EDL, extensor digitorum longus; GM, gluteus magnus; H&E,
hematoxylin–eosin; LAMP-2, lysosome-associated membrane protein-2;
OM, original magnification; PAS, periodic acid–Schiff; RF, rectus femoris;
RYR1, ryanodine receptor 1; S, soleus; SM, semimembranous; ST, sem-
itendinous; TA, tibialis anterior; VL, vastus lateralis; VM, vastus medialis; V-
ATPase, vacuolar adenosine triphophatase; XMEA, X-linked myopathy
with excessive autophagy
Key words: excessive autophagy; muscle MRI; myopathy; VMA21; XMEA
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